Mylan Launches Generic Seasonale in U.S. Market
Mylan has expanded its portfolio of oral contraceptives with the U.S. release of a generic formulation of Teva’s Seasonale.
The launch of generic Seasonale (levonorgestrel and ethinyl estradiol) in 0.15 mg/0.03 mg tablets follows this week’s FDA approval of an ANDA submitted by Mylan’s partner, Famy Care Ltd. The product is Mylan’s tenth oral contraceptive for the U.S market.
Seasonale had revenues of about $81.2 million in 2012, according to IMS Health.
The generic release comes as Mylan continues to fight off an unfriendly takeover bid by Teva, while Irish drugmaker Perrigo rejects similar offers from Mylan. — Jessica Grinspan